P2.09. Trials in Progress: Phase 1a/b study of ELVN-002, in Solid Tumors with HER2 Mutations, Amplification or Overexpression - PDF(Abstract)
Back to course
Pdf Summary
Asset Subtitle
Samantha Bowyer
Meta Tag
Speaker Samantha Bowyer
Topic Metastatic NSCLC: Targeted Therapy - EGFR/HER2
clinical trial
HER2 mutations
solid tumors
tyrosine kinase inhibitor
dose escalation
HER2-mutant NSCLC
combination therapy
Enliven Therapeutics
Powered By